EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Downregulation of ACAN is Associated with the Growth hormone pathway and Induces short stature

Huiping Wu, Chaoban Wang, Shiwen Yu, Xiaojun Ye, Yalan Jiang, Pingping He, Xiaoou Shan iD

Journal of Clinical Laboratory Analysis · 2023

DOI: 10.1002/jcla.24830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Huiping Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrine, Yuying Children's Hospital, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Aggrecans, Dwarfism, Human Growth Hormone. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ACAN heterozygous mutations can cause short stature in patients with or without advanced bone age and have recently attracted researchers' attention. Growth hormone can be used to treat short stature induced by ACAN mutations; however, few studies have focused on the underlying mechanism of this treatment.

Methods

Four patients with new mutations were reported based on clinical data and genetic tests. We investigated the expression and Gene Ontology biological process enrichment of ACAN and GH pathways based on GTEx databases through bioinformatics analyses. The effect of ACAN on the growth hormone response evaluated in ATDC5 cells with a growth hormone stimulation test.

Results

Four mutations were reported in this study: c.619C > A, c.1967A > G, c.1888G > A, and c.1308_1309del. All patients' heights were under −2.5 SD, with one had advanced bone age, and two had GH deficiency. Two individuals received growth hormone therapy acquired variable levels of height SD score improvement. ACAN and the GH pathway were strongly associated; ACAN does not affect GHR but regulates the response to GH. Downregulating ACAN inhibited ATDC5 cell proliferation induced by GH.

Conclusion

ACAN is associated with the GH pathway, revealing the potential mechanism underlying GH‐targeted treatment for ACAN mutation‐induced short stature. GH‐promoting therapies may increase patients' heights.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AggrecansDwarfismHuman Growth HormoneHumansDown-RegulationGenetic TestingGrowth HormoneMutation

Stichwörter der Autor:innen

ACANgrowth hormoneshort staturetreatment

Substanzen

ACAN protein, humanAggrecansGrowth HormoneHuman Growth Hormone

Autor:innen und Institutionen

  • Department of Pediatric Endocrine, Yuying Children's Hospital, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Xiaoou Shan

Zitieren

APA

Wu, H., Wang, C., Yu, S., Ye, X., Jiang, Y., He, P., & Shan, X. (2023). Downregulation of ACAN is Associated with the Growth hormone pathway and Induces short stature. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24830

Vancouver

Wu H, Wang C, Yu S, Ye X, Jiang Y, He P, et al. Downregulation of ACAN is Associated with the Growth hormone pathway and Induces short stature. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24830

BibTeX
@article{Wu2023,
  author = {Wu, Huiping and Wang, Chaoban and Yu, Shiwen and Ye, Xiaojun and Jiang, Yalan and He, Pingping and Shan, Xiaoou},
  title = {Downregulation of ACAN is Associated with the Growth hormone pathway and Induces short stature},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2023},
  doi = {10.1002/jcla.24830}
}
Kostenlos starten →